Unrelenting drive

Our mission is to rapidly and unequivocally change the face of medicine

Bold, yes. But we believe achievable by working to deliver on the promise of personalized medicine for the most difficult-to-treat diseases.
drive-mobile-graphic
Unrelenting drive

What we stand for

Our values are more than words. They inspire our hiring practice, guide our decision-making and make us who we are.

Patients first

We maintain intense focus on improving patients’ lives

Thoughtfulness

We explore creative approaches, daring to make well-thought-out decisions and owning the outcomes

Urgency

We solve complex problems rapidly, with attention and care

Trust

Through collaboration and cooperation, we build and maintain a cohesive team that has mutual respect of different viewpoints and talents

Optimism

We pursue transformative therapies that we believe will make a difference

Our story

drive-slide-bg

2011

Led by the pioneers of highly successful kinase inhibitors including Gleevec® (imatinib), our scientific founders launch the company with a vision to revolutionize how kinase medicines are discovered and developed.

2011-2014

Our foundational work focuses on development of a proprietary library of novel compounds that are fully annotated against the human kinome. This library becomes the basis for the company’s successful drug discovery efforts.

2015

We publish foundational preclinical data for the first selective FGFR4 inhibitor for the treatment of patients with FGFR4-activated hepatocellular carcinoma in Cancer Discovery, supporting the advancement of our therapeutic candidate BLU-554.

2015

Blueprint Medicines launches an initial public offering on the Nasdaq stock exchange.

2015

We initiate clinical development of avapritinib in patients with advanced gastrointestinal stromal tumors and patients with systemic mastocytosis.

2015

We initiate clinical development of BLU-554 in patients with hepatocellular carcinoma.

2016

Blueprint Medicines and Roche enter into a global collaboration to develop up to five novel kinase medicines in the field of cancer immunotherapy.

2016

Clinical proof-of-concept data for avapritinib in patients with advanced gastrointestinal stromal tumors is reported at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics.

2017

We initiate clinical development of BLU-667 in patients with RET-altered cancers.

2017

Avapritinib receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRα D842V mutation.

2017

Foundational preclinical data and clinical cases for avapritinib in advanced gastrointestinal stromal tumors are published in Science Translational Medicine.

2017

Preliminary Phase 1 clinical data for avapritinib in patients with advanced systemic mastocytosis are selected among more than 6,000 abstracts for presentation during the scientific plenary session at the American Society of Hematology annual meeting.

2018

To support our continued growth and pipeline success, we relocate to new offices in Cambridge, Massachusetts.

2018

Clinical proof-of-concept data for BLU-667 in patients with RET-altered cancers is reported at a clinical trials plenary session at the American Association for Cancer Research annual meeting and published in Cancer Discovery.

2018

Blueprint Medicines and CStone Pharmaceuticals announce strategic collaboration to develop and commercialize avapritinib, BLU-554 and BLU-667 in Mainland China, Hong Kong, Macau and Taiwan.

2018

Avapritinib receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of advanced systemic mastocytosis.

2019

BLU-667 receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of RET-mutation-positive medullary thyroid cancer that requires systemic treatment and for which there are no acceptable alternative treatments.

2019

BLU-667 receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of RET-fusion-positive non-small cell lung cancer that has progressed following platinum-based chemotherapy.